Listing & Compliance Notices

LUXURBAN HOTELS INC. received a nasdaq compliance regained notice regarding market value (rules 5550(b)(2)).

“tock”) and 13.00% Series A Cumulative Redeemable Preferred Stock, $0.00001 par value per share (“preferred stock”, and collectively with the common stock the “securities”) had been below the minimum of $35 million required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The notice stated that the Company would be afforded 180 calendar days (until December 26, 2024) (the “Compliance Period”) to regain compliance. On January 3, 2024, the Company received a notice from Nasdaq indicating that it has not regained compliance with Nasdaq Listing Rule 5550(b)(2”

Adagio Medical Holdings, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(c)(4)).

“January 2, 2025, the Company r eceived a letter from the Listing Qualifications Staff (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that, due to the vacancy on the audit committee of the Company’s Board of Directors (the “ Board ”) following Shahram Moaddeb’s resignation from the Board as disclosed in the Company's Current Report on Form 8-K filed with the SEC on December 23, 2024, the Company is not in compliance with Nasdaq’s audit committee requirements as set forth in Listing Rule 5605. Under Nasdaq Listing Rule 5605(c)(4), Nasdaq provided the Company a cure period”

BP PRUDHOE BAY ROYALTY TRUST received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“December 31, 2024, the Trust received written notification (the “Notice”) from the New York Stock Exchange (“NYSE”) that as of December 30, 2024, the Trust no longer satisfied the continued listing compliance standards set forth under Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Trust’s units of beneficial interest (the “Units”) was less than $1.00 over a 30 consecutive trading-day period. Upon receipt of the Notice, the Trust became subject to the procedures outlined in Section 802.01C of the NYSE Listed Company Manual and the Trust must bring the”

Algorhythm Holdings, Inc. received a nasdaq deficiency notice notice regarding other (rules 5810(c)(3)(A)(iii)).

“December 30, 2024, the Company received notice from the Staff indicating that the bid price for the Company’s common stock had closed below $0.10 per share for the 13-consecutive trading day period ended December 27, 2024 and, accordingly, the Company is subject to the provisions contemplated under Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stock Rule”) and its securities are subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will”

Algorhythm Holdings, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5810(c)(3)(A)(iii)).

“December 30, 2024, the Company received notice from the Staff indicating that the bid price for the Company’s common stock had closed below $0.10 per share for the 13-consecutive trading day period ended December 27, 202”

BP PRUDHOE BAY ROYALTY TRUST received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“December 31, 2024, the Trust received written notification (the “Notice”) from the New York Stock Exchange (“NYSE”) that as of December 30, 2024, the Trust no longer satisfied the continued listing compliance standards s”

Adagio Medical Holdings, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(4)).

“January 2, 2025, the Company r eceived a letter from the Listing Qualifications Staff (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that, due to the vacancy on the audit committee of the Company’”

LUXURBAN HOTELS INC. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“minimum of $35 million required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The notice stated that the Company would be afforded 180 calendar days (until December 26, 2024) (”

Real Good Food Company, Inc. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“January 3, 2025, The Real Good Food Company, Inc. (the “Company ”), received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) that it has determined to delist the Company’s common stock on Nasdaq. The delisting is a”

Brand Engagement Network Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“December 30, 2024, Brand Engagement Network Inc., a Delaware corporation (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”)”

CEMTREX INC received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“January 2, 2025, the Company received a letter from Nasdaq notifying the Company that based on the Company’s Form 10-K filed on December 30, 2024, evidencing stockholders’ equity of $4,710,677, Nasdaq has determined that”

LUNA INNOVATIONS INC received a nasdaq noncompliance notice notice regarding shareholders (rules 5620(a)).

“January 3, 2025, the Company received formal notice (the “Notice”) from Nasdaq that trading in the Company’s common stock will be suspended on Nasdaq effective with the open of business on Tuesday, January 7, 2025, and”

LUNA INNOVATIONS INC received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“January 3, 2025, the Company received formal notice (the “Notice”) from Nasdaq that trading in the Company’s common stock will be suspended on Nasdaq effective with the open of business on Tuesday, January 7, 2025, and”

Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 30, 2024, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closi”

Valion Bio, Inc. received a nasdaq delisting notice notice regarding stockholders equity.

“December 27, 2024, the Company received an additional letter from Nasdaq, notifying the Company that it has not regained compliance with the Rule and is not eligible for a second 180-day remediation period. Specifically”

Valion Bio, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 27, 2024, the Company received an additional letter from Nasdaq, notifying the Company that it has not regained compliance with the Rule and is not eligible for a second 180-day remediation period. Specifically”

iLearningEngines, Inc. received a nasdaq delisting notice notice regarding other (rules 5110(b), IM-5101-1).

“December 23, 2024 notifying the Company that, in connection with the Company’s December 23, 2024 announcement that it had filed for protection under Chapter 11 of the Bankruptcy Code, and in accordance with Nasdaq Listin”

Forge Global Holdings, Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“December 31, 2024, Forge Global Holdings, Inc. (the “Company”) received written notice from the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with Rule 802.01C of the NYSE’s Listed Company Ma”

KUSTOM ENTERTAINMENT, INC. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“January 2, 2025, Nasdaq delivered a written notification notifying the Company that it had regained compliance with the Quarterly Report Requirement. Minimum Stockholders’ Equity Standard On January 2, 2025, the Company”

KUSTOM ENTERTAINMENT, INC. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“November 27, 2024, Digital Ally, Inc. (the “Company”) received a notice from the Nasdaq Stock Market LLC (“Nasdaq”), which indicated that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q fo”

cbdMD, Inc. received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(i)).

“December 31, 2024, cbdMD, Inc. (the “Company”) received notification (the “Notice”) from the NYSE American LLC (the “NYSE American”) that the Company is no longer in compliance with an additional NYSE American continued”

Bolt Biotherapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“January 2, 2025, the Company received written notice from Nasdaq notifying the Company that its application to transfer the listing of its common stock to The Nasdaq Capital Market was approved. The approval is based upo”

BioNexus Gene Lab Corp received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“December 27, 2024, BioNexus Gene Lab Corp. (the “Company”) received a written notice from the Nasdaq Hearings Panel (the “Panel”) indicating that the Company has been granted a temporary exception to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Bid Price Rule”). The Company has until May 1, 2025, to regain compliance. As part of this compliance plan, the Company intends to effect a reverse stock split, if necessary, no later than April 7, 2025, and has outlined steps to meet this timeline. Failure to regain compliance by May”

NOODLES & Co received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“cember 24th, 2024, Noodles & Company (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Global Select Market.”

XMax Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 27, 2024, Nova LifeStyle, Inc. (the “Company”) received a letter from the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer meets the minimum bid price requirement for continued listing on Nasdaq under Nasdaq Marketplace Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). The notification has no immediate effect on the listing of the Company’s common stock. In accordance w”

Glucotrack, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 31, 2024, Nasdaq Stock Market LLC (“Nasdaq”) notified Glucotrack, Inc. (the “Company”) that for at least the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until June 30, 2025, to regain compliance with the Bid Price Rule. If at any time before June 30, 2025, the bi”

Tempest Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 27, 2024, Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s common stock on the Nasdaq Stock Market. In accordance with”

Danimer Scientific, Inc. received a nyse delisting notice notice regarding market value (rules 802.01B).

“December 30, 2024, the New York Stock Exchange (“NYSE”) notified Danimer Scientific Inc. (“Danimer” or the “Company”) that it has determined to commence proceedings to delist the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), as a result of the Company’s non-compliance with Rule 802.01B of the NYSE Listed Company Manual that requires listing companies to maintain an average global market capitalization of at least $15 million over a period of 30 consecutive trading days. Trading in the Common Stock on the NYSE was suspended after market close on December 30”

Vaxart, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“en notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. The Notice did not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company originally had 180 calendar days, or until December 30, 2024, to regain compliance by maintaining a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading days. Pursuant to the Extension Letter, the Company now has until June 30, 2025”

Aspira Women's Health Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“December 31, 2024, the Company received written notice from the Staff of Nasdaq notifying it that the Company failed to regain compliance with the MVLS Requirement by the Compliance Date. As such, unless the Company requests an appeal of Nasdaq’s determination to delist the Company’s common stock from The Nasdaq Capital Market by January 7, 2025 and pays Nasdaq a hearing fee of $20,000, the Company’s common stock will be delisted from The Nasdaq Capital Market at the opening of business on January 10, 2025. While the Company intends to appeal Nasdaq’s decision, no guarantee can be provided tha”

VerifyMe, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 27, 2024, VerifyMe, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of at least $1 per share. Nasdaq Listing Rule 5810(c)(3)(A) provides a compliance period of 180 calendar days, or until June 25, 2025, in which to regain compliance with the minimum bid price requirement.”

CBAK Energy Technology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 26, 2024, CBAK Energy Technology, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of US$1.00 per share. Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on”

CapForce Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“December 19, 2024, despite OpGen, Inc. (the “Company”) regaining short-term compliance with the minimum stockholders’ equity requirement of the Nasdaq Capital Market (“Nasdaq”) pursuant to Nasdaq Listing Rule 5550(b)(1) after the deadline for such compliance granted to the Company prior to AEI Capital Ltd. acquiring a controlling interest in the Company, the Nasdaq Listing and Hearing Review Council (the “Listing Council”) affirmed the decision of the Nasdaq Hearings Panel (the “Panel”). As previously disclosed, on August 16, 2024, the Company received written notice of the Panel’s determinati”

Invivyd, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“December 27, 2024, Invivyd, Inc. (the “Company”) received a deficiency letter (the “ Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock, $0.0001 par value per share (the “Common Stock”), had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Letter has no immediate effect on the l”

iLearningEngines, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“December 23, 2024, iLearningEngines , Inc. (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, in connection with the Company’s December 23, 2024 announcement that it had filed for protection under Chapter 11 of the U.S. Bankruptcy Code, and in accordance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1, the Nasdaq Staff had determined to delist the Company’s securities from The Nasdaq Stock Market. The Notice further states that trading in the Company’s common stock and wa”

IO Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“December 26, 2024, IO Biotech, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Select Market, and the Company’s commo”

Global Star Acquisition Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C)).

“December 18, 2024, Global Star Acquisition Inc. (the “Company”) received a letter from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that based upon Nasdaq’s review of the Company’s Market Value of Publicly Held Shares (“MVPHS”) for the last 30 consecutive business days prior to the date of the letter, the Company no longer meets the requirements of Nasdaq Listing Rule 5450(b)(2)(C), which requires listed securities to maintain a minimum MVPHS of $15,000,000 (the “MVPHS Requirement”). The Company intends to monitor the market value o”

ProPhase Labs, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 26, 2024, ProPhase Labs, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price for the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Nasdaq Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180 calendar day grace period, or until June 24, 2025, to regain compliance with the minimum bid price requirement. The continued listing standa”

CRESCENT BIOPHARMA, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“December 19, 2024, GlycoMimetics, Inc. (the “ Company ”) received a notice (the “ Extension Notice ”) from the Listing Qualifications Department of the Nasdaq Stock Market (“ Nasdaq ”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until June 16, 2025, to regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “ Rule ”). In connection with the Extension Notice, the listing of the Company’s common stock was transferred from the Nasdaq Global Market to”

KUSTOM ENTERTAINMENT, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 20, 2024, Digital Ally, Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), which indicated that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), as the Company’s closing bid price for its common stock, par value $0.001 per share (“Common Stock”), was below $1.00 per share for the prior thirty (30) consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until June 18, 2025 (the “Compliance Per”

SeaStar Medical Holding Corp received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

“December 24, 2024, the Company received written notification (the “Notification”) from Nasdaq stating that the Company had not regained compliance with the Rule. Pursuant to the Notification, the Securities are subject to delisting from Nasdaq on January 3, 2025, unless the Company requests a hearing before the Nasdaq Hearings Panel (the “Panel”) by December 31, 2024. The Company intends to appeal the delisting determination before the Panel and regain compliance with the Rule. Under Nasdaq rules, the delisting of the Securities will be stayed during the pendency of the appeal and during such”

Volato Group, Inc. received a nyse_american deficiency notice notice regarding other (rules 301, 713).

“December 19, 2024, Volato Group, Inc. (the “Company”) received from NYSE Regulation a Warning Letter (the “Letter”) as provided under Section 1009(a) of the NYSE American LLC ("NYSE American") Company Guide (the “Company Guide”) describing violations by the Company of Sections 301 and 713 of the Company Guide. Section 301 of the Company Guide prohibits a listed company from issuing, or authorizing its transfer agent or registrar to issue or register, additional securities of a listed class until it has filed an application for the listing of such additional securities and received notification”

KIDPIK CORP. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“December 20, 2024, Kidpik Corp. (the “ Company ”, “ we ” and “ us ”) received notice from The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Nasdaq Hearings Panel (the “ Panel ”) has determined to delist the Company’s securities from Nasdaq based upon the Company’s non-compliance with Listing Rule 5550(b)(1), the Exchange’s minimum shareholders’ equity rule (the “ Equity Rule ”). As a result of the Panel’s decision, Nasdaq will suspend trading in the Company’s securities effective at the open of business on Thursday, December 26, 2024. The Company anticipates that, concurrent with th”

Strive, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 16, 2024, Asset Entities Inc., a Nevada corporation (the “Company”), received a written notification (the “Notification Letter”), from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market tier of Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides tha”

INGLES MARKETS INC received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“December 20, 2024, Ingles Markets, Incorporated, a North Carolina corporation (the “Company”), received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that because the Company had not yet filed its Annual Report on Form 10-K for the fiscal year ended September 28, 2024 (the “Annual Report”), the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. The Notice has no immediate effect on th”

Arena Group Holdings, Inc. received a nyse_american extension granted notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).

“December 20, 2024, The Arena Group Holdings, Inc. (the “Company”) was notified by NYSE American LLC (“NYSE American”) that the Company’s plan to regain compliance with NYSE American’s continued listing standards had been accepted. The Company was required to submit a plan to NYSE American by November 1, 2024 addressing how it intends to regain compliance with Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the Company Guide by April 2, 2026. The Company submitted a plan prior to the deadline. On December 20, 2024, the Company received notice from NYSE American that it had accepted the Com”

ALTISOURCE PORTFOLIO SOLUTIONS S.A. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“December 19, 2024, Altisource Portfolio Solutions S.A. (the “Company”) received a letter (the “Bid Price Notice”) from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, because the closing bid price for its common stock has been below $1.00 per share for 30 consecutive business days, it no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Rule”), and Nasdaq Listing Rule 5810(c)(3)(A) prov”

Crown Electrokinetics Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5815(d)(4)(B)).

“December 19, 2024, Crown Electrokinetics Corp. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the thirty (30) consecutive business days prior to the letter, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). As previously disclosed on July 26, 2024, on May 7, 2024, the Company attended a hearing (the “Hearing”) before the Nasdaq”

HCW Biologics Inc. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(3)(A)).

“December 17, 2024, the Staff notified the Company that its securities were subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq pending the hearing and the expiration of any extension that may be granted to the Company following the hearing. At the hearing, the Company will present its plan to evidence compliance with all applicable listing criteria, including the MVLS Rule, and request an extension of time”

Pearl Holdings Acquisition Corp received a nasdaq delisting notice notice regarding other (rules IM-5101-2).

“ities and Exchange Commission, which will remove the Securities from listing and registration on Nasdaq. Pursuant to Nasdaq’s procedures, the Company may appeal the Staff’s determination. However, the Staff may only reverse its delisting determination if it finds it made a factual error in applying Rule 5101-2 and that the Company never failed to satisfy the requirement set forth in Rule 5101-2. The Company does not intend to exercise its right to appeal. Some or all of the Securities may be quoted on an over-the-counter market following the suspension of trading on The Nasdaq Global Market an”